MedPath

Anhedonia and reward processing deficits in schizophrenia and major depressive disorder

Completed
Conditions
depression
psychosis
10037176
Registration Number
NL-OMON48457
Lead Sponsor
niversiteit Maastricht
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
40
Inclusion Criteria

All groups:
- male/female
- age 20-55
- be able to read, write, and speak the language in which psychometric tests
are provided

Schizophrenia group
- Primary diagnosis of schizophrenia (according to DSM-V)

Depression group
- Primary diagnosis of major depressive disorder (according to DSM-V)

Exclusion Criteria

All groups:
- history of substance abuse (DSM-V)
- history of neurological disorder (Parkinson's, epilepsy, Alzheimer's)
- diagnosis of mental retardationTwo patient groups:
- Bipolar disorder (DSM-V)
- Obsessive-Compulsive disorder (DSM-V)
- Eating disorder (DSM-V)
- Attention-deficit hyperactivity disorder (DSM-V)
- Received treatment with clozapine in the last 6 months before screening.
- Experienced an acute exacerbation requiring hospitalization within the last 3
months.
- major changes to medication (~30% dose change) in the 4 weeks prior to
participation

Study & Design

Study Type
Observational non invasive
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
<p>We will use one main outcome measure per task as a formal primary endpoint. As<br /><br>a primary study endpoint for the Grip Strength task we will compare the<br /><br>percentage of hard task choices at different reward levels in the Grip Strength<br /><br>Task, which will be compared at a group level between MDD vs. matched healthy<br /><br>controls, SZ vs. matched healthy controls, and MDD vs SZ. For the Reinforcement<br /><br>Learning/Working Memory task, we will compare the number of optimal choices per<br /><br>set size condition (2-5) between these groups, and for the Doors task,<br /><br>percentage of trials on which a participant choose the other door after<br /><br>experiencing a loss (*lose-shifting*). The test-retest reliability of these<br /><br>outcome measures will be investigated.</p><br>
Secondary Outcome Measures
NameTimeMethod
<p>- We will compare group-level (control, MDD, SZ) means and distributions<br /><br>(standard deviations) of our primary endpoints with previously published work.<br /><br>- Per task, we will compare event-related potential (ERPs, obtained from the<br /><br>EEG data) between the three groups<br /><br>- Relationships between primary task endpoints, EEG endpoints and symptom<br /><br>severity (SHAPS sum scores) will be investigated using correlational analyses<br /><br>- the intraclass correlation coefficient for all outcome measures mentioned<br /><br>under point 1 and 2 will be investigated.</p><br>
© Copyright 2025. All Rights Reserved by MedPath